Supreme Court Preserves Mail-Order Access to Abortion Pill Mifepristone
In a high-stakes emergency ruling on Thursday, May 14th, 2026, the U.S. Supreme Court ensured that the abortion medication mifepristone will remain available via mail and telehealth. The 7-2 decision blocks a lower court's attempt to reinstate strict in-person requirements while a legal challenge from the state of Louisiana continues to move through the system.
The "shadow-docket" order was issued shortly after the court missed its own 5 p.m. deadline. It effectively hits the brakes on a May 1st ruling by the 5th U.S. Circuit Court of Appeals, which had sided with Louisiana to curtail the Food and Drug Administration's (FDA) ability to allow remote prescriptions.
Louisiana’s lawsuit argues that the FDA’s 2023 decision to permanently allow mail-order pills interferes with the state's near-total abortion ban. The state’s attorneys claimed that "Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is human being from the moment of conception and is, therefore, a legal person."
However, drug manufacturers Danco Laboratories and GenBioPro argued that Louisiana lacked the standing to challenge federal regulations. Reproductive rights advocates emphasized that medication abortion now accounts for approximately two-thirds of all pregnancy terminations in the U.S., making mail access a critical lifeline in states with restrictive laws.
The court’s most conservative members, Justices Clarence Thomas and Samuel Alito, stood in firm opposition to the stay. In a scathing dissent, Justice Thomas characterized the drug manufacturers' operations as a "criminal enterprise" and argued that the 1873 Comstock Act, an anti-obscenity law, prohibits the mailing of abortion-related items.
Justice Alito echoed these concerns, stating that "What is at stake is the perpetration of a scheme to undermine our decision in Dobbs v Jackson Women’s Health Organization," the 2022 ruling that ended the federal right to abortion.
The Supreme Court's order is not a final ruling on the merits of the case but a "stay" that keeps the status quo in place. The litigation will now return to the 5th Circuit, and the case is widely expected to land back on the Supreme Court's official docket next year.
The FDA noted in a statement on X that it "will press forward to complete its science-based safety review of the mifepristone REMS" to provide greater transparency. While the ruling provides temporary relief for providers and patients, activists warn that other Republican-led states are already filing similar lawsuits targeting the drug’s initial approval from the year 2000.
For now, mifepristone, which medical experts such as Camille Clare of the American College of Obstetricians and Gynecologists describe as "one of the safest and most well-studied drugs on the market", remains accessible nationwide.
